Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vor Bio Announced Telitacicept Achieved Primary Endpoint Of Reducing Proteinuria In Stage A Of Phase 3 Clinical Study For IgA Nephropathy In China; Statistically Significant Benefits Also Achieved Across All Key Secondary Endpoints

Author: Benzinga Newsdesk | November 08, 2025 11:55am

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile

Telitacicept demonstrated a 55% reduction in 24-hour urine protein-to-creatinine ratio (24h-UPCR) at 39 weeks compared with placebo; statistically significant benefits also achieved across all key secondary endpoints

Data presented as late-breaking oral presentation at American Society of Nephrology's Kidney Week 2025

Posted In: VOR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist